Free Trial
→ Musk is burning $2.5 billion a quarter on AI. One company holds the key. (From Behind the Markets) (Ad)tc pixel Free CCCC Stock Alerts

C4 Therapeutics (CCCC) Short Interest Ratio & Short Volume

C4 Therapeutics logo
$3.87 +0.29 (+8.10%)
Closing price 04:00 PM Eastern
Extended Trading
$3.80 -0.08 (-1.94%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

C4 Therapeutics Short Interest Overview

As of May 29, 2026, C4 Therapeutics (CCCC) had a short interest of 21.65 million shares sold short, representing 20.74% of the public float. This marks a 1.86% increase in short interest since the prior report. The short interest ratio (days to cover) is 9.4, meaning it would take 9.4 days of the average trading volume of 2.88 million shares to cover all short positions.

Current Short Interest
21,650,001 shares
Previous Short Interest
21,254,462 shares
Change Vs. Previous Month
1.86%
Dollar Volume Sold Short
$94.61 million
Short Interest Ratio
9.4 Days to Cover
Last Record Date
May 29, 2026
Outstanding Shares
110,570,000 shares
Short Percent of Float
20.74%
Today's Trading Volume
2,277,144 shares
Average Trading Volume
2,878,574 shares
Today's Volume Vs. Average
79%
Short Selling C4 Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for C4 Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

CCCC Short Interest Over Time

CCCC Days to Cover Over Time

CCCC Percentage of Float Shorted Over Time

C4 Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/29/202621,650,001 shares $94.61 million +1.9%20.7%9.43 $4.37
5/15/202621,254,462 shares $75.67 million +1.0%20.4%5.81 $3.56
4/30/202621,055,109 shares $59.59 million +0.1%20.2%10.88 $2.83
4/15/202621,042,260 shares $60.81 million +30.2%23.6%5.05 $2.89
3/31/202616,157,271 shares $42.49 million +19.4%18.1%8.42 $2.63
3/13/202613,534,910 shares $36.81 million +58.8%15.2%3.74 $2.72
2/27/20268,520,947 shares $23.01 million +19.7%9.6%3.4 $2.70
2/13/20267,121,324 shares $13.46 million -1.2%8.1%8.19 $1.89
1/30/20267,207,214 shares $13.69 million -2.3%8.1%3.84 $1.90
1/15/20267,379,826 shares $16.38 million +1.4%8.3%5.79 $2.22
12/31/20257,281,152 shares $13.91 million +1.5%8.2%3.5 $1.91
12/15/20257,172,653 shares $17.43 million +28.4%8.1%4.38 $2.43
11/28/20255,588,028 shares $14.92 million +15.3%6.3%4.84 $2.67
11/14/20254,848,155 shares $11.97 million +0.8%5.5%2.92 $2.47
10/31/20254,811,669 shares $12.56 million +20.7%7.4%1.89 $2.61
10/15/20253,990,000 shares $8.86 million +13.4%6.1%2 $2.22
9/30/20253,520,000 shares $7.81 million -0.6%N/A1.9 $2.22
9/15/20253,540,000 shares $12.64 million -6.4%N/A2.1 $3.57
8/31/20253,780,000 shares $9.83 million -8.9%5.8%2.5 $2.60
8/15/20254,150,000 shares $10.21 million -10.9%N/A2.8 $2.46
7/31/20254,660,000 shares $9.55 million +14.5%7.2%3.2 $2.05
7/15/20254,070,000 shares $8.59 million -17.9%N/A2.9 $2.11
6/30/20254,960,000 shares $7.09 million -22.3%7.7%3.9 $1.43
6/15/20256,380,000 shares $10.72 million +3.4%9.8%5.8 $1.68
5/31/20256,170,000 shares $7.62 million -3.0%9.6%5.8 $1.24
5/15/20256,360,000 shares $8.78 million -0.8%9.9%5.7 $1.38
4/30/20256,410,000 shares $10.51 million -17.1%N/A5.1 $1.64
4/15/20257,730,000 shares $9.20 million -0.4%12.0%5.6 $1.19
3/31/20257,760,000 shares $12.42 million -5.0%12.0%5.4 $1.60
3/15/20258,170,000 shares $16.59 million -4.4%12.7%5 $2.03
2/28/20258,550,000 shares $23.17 million +6.1%13.2%4.7 $2.71
2/15/20258,060,000 shares $25.63 million +8.9%12.5%4.4 $3.18
1/31/20257,400,000 shares $25.68 million -20.3%N/A4.4 $3.47
1/15/20259,280,000 shares $37.49 million +7.9%N/A6 $4.04
12/31/20248,600,000 shares $30.96 million -3.0%N/A6.4 $3.60
12/15/20248,870,000 shares $38.85 million +11.0%N/A7.3 $4.38
11/30/20247,990,000 shares $36.35 million +8.0%N/A7.3 $4.55
11/15/20247,400,000 shares $31.89 million +26.5%N/A7.3 $4.31
10/31/20245,850,000 shares $31.18 million -12.0%N/A6 $5.33
10/15/20246,650,000 shares $41.90 million -39.6%N/A6.7 $6.30
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad)

Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel

Get the name and ticker of Louis Navellier's #1 AI stock free
9/30/202411,010,000 shares $62.76 million -7.6%N/A9 $5.70
9/15/202411,920,000 shares $76.76 million +2.5%N/A8.1 $6.44
8/31/202411,630,000 shares $73.50 million +10.8%N/A7.4 $6.32
8/15/202410,500,000 shares $61.53 million +0.3%N/A6.6 $5.86
7/31/202410,470,000 shares $70.15 million -10.0%N/A6.3 $6.70
7/15/202411,630,000 shares $75.48 million +32.0%N/A7 $6.49
6/30/20248,810,000 shares $40.70 million -39.4%N/A5.7 $4.62
6/15/202414,540,000 shares $63.69 million +9.7%N/A10.2 $4.38
5/31/202413,260,000 shares $66.30 million +16.9%N/A8.4 $5.00
5/15/202411,340,000 shares $69.29 million +11.8%N/A5.9 $6.11
4/30/202410,140,000 shares $63.88 million +6.1%N/A4.5 $6.30
4/15/20249,560,000 shares $65.58 million +4.5%N/A3.7 $6.86
3/31/20249,150,000 shares $74.76 million +73.0%N/A2.4 $8.17
3/15/20245,290,000 shares $47.24 million +78.1%N/A1.1 $8.93
2/29/20242,970,000 shares $32.61 million -6.6%N/A0.2 $10.98
2/15/20243,180,000 shares $25.12 million -5.1%N/A0.2 $7.90
1/31/20243,350,000 shares $20.70 million -39.6%8.7%0.2 $6.18
1/15/20245,550,000 shares $37.74 million +22.3%14.5%0.4 $6.80
12/31/20234,540,000 shares $25.65 million -44.0%10.8%0.3 $5.65
12/15/20238,100,000 shares $40.10 million +330.9%19.3%0.7 $4.95
11/30/20231,880,000 shares $3.06 million -3.6%4.5%3.4 $1.63
11/15/20231,950,000 shares $3.51 million +2.1%4.7%4.1 $1.80
10/31/20231,910,000 shares $2.85 million +4.4%4.6%3.9 $1.49
10/15/20231,830,000 shares $3.64 million -19.0%4.6%3.8 $1.99
9/30/20232,260,000 shares $4.20 million -5.0%5.6%5.2 $1.86
9/15/20232,380,000 shares $5.31 million +14.4%5.9%2.4 $2.23
8/31/20232,080,000 shares $6.03 million +9.5%5.2%1.9 $2.90
8/15/20231,900,000 shares $6.42 million -10.0%4.7%1.6 $3.38
7/31/20232,110,000 shares $8.21 million -5.8%5.3%1.7 $3.89
7/15/20232,240,000 shares $7.50 million -8.9%5.6%1.8 $3.35
6/30/20232,460,000 shares $6.77 million -26.4%6.1%2 $2.75
6/15/20233,340,000 shares $12.06 million +2.8%8.3%5.1 $3.61
5/31/20233,250,000 shares $11.02 million +12.1%8.1%5.4 $3.39
5/15/20232,900,000 shares $9.69 million +0.7%7.2%5.2 $3.34
4/30/20232,880,000 shares $8.70 million +1.8%7.0%5 $3.02
4/15/20232,830,000 shares $9.48 million +7.6%6.9%4.9 $3.35
3/31/20232,630,000 shares $8.26 million -9.9%6.5%4.5 $3.14
3/15/20232,920,000 shares $12.59 million -10.2%7.2%5.1 $4.31
2/28/20233,250,000 shares $17.13 million +0.9%8.0%6.3 $5.27
2/15/20233,220,000 shares $18.58 million -12.5%7.9%6.1 $5.77
1/31/20233,680,000 shares $28.67 million +2.8%9.0%7 $7.79
1/15/20233,580,000 shares $30.57 million +2.0%8.8%7.8 $8.54
12/30/20223,510,000 shares $20.71 million -3.6%8.6%7.8 $5.90
12/15/20223,640,000 shares $29.48 million +0.3%8.9%8 $8.10
11/30/20223,630,000 shares $31.11 million -8.1%8.9%7.5 $8.57
11/15/20223,950,000 shares $38.39 million -19.1%9.7%8.5 $9.72
10/31/20224,880,000 shares $46.95 million -1.2%11.9%11.4 $9.62
10/15/20224,940,000 shares $39.32 million -2.0%12.9%12.1 $7.96
9/30/20225,040,000 shares $44.20 million +11.0%13.2%11.9 $8.77
9/15/20224,540,000 shares $51.57 million -6.8%11.8%9.8 $11.36
Live demo of Elon Musk’s AI agent (Ad)

Jeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's zeroing in on Elon Musk's new AI agent, which Musk himself believes could return 70 times investors' money. Brown, who correctly predicted the SpaceX IPO and held Tesla when experts turned bearish, says an announcement is expected by end of month that could make this AI agent available to every American. He's offering a free live demo and ground-floor access details right now.tc pixel

Watch the free live demo and learn how to get in today
8/31/20224,870,000 shares $49.09 million -5.1%12.7%9.9 $10.08
8/15/20225,130,000 shares $62.23 million -3.2%13.4%9.2 $12.13
7/31/20225,300,000 shares $51.09 million +1.5%13.9%8.2 $9.64
7/15/20225,220,000 shares $52.30 million +2.8%13.7%7.2 $10.02
6/30/20225,080,000 shares $38.30 million +20.7%13.3%4.7 $7.54
6/15/20224,210,000 shares $23.11 million -2.1%11.0%3.7 $5.49
5/31/20224,300,000 shares $31.22 million +10.3%11.3%4.2 $7.26
5/15/20223,900,000 shares $27.89 million -23.7%10.2%3.9 $7.15
4/30/20225,110,000 shares $43.79 million -4.7%13.4%5.4 $8.57
4/15/20225,360,000 shares $47.97 million +4.7%14.0%5.8 $8.95
3/31/20225,120,000 shares $124.21 million +8.5%13.4%7.2 $24.26
3/15/20224,720,000 shares $101.48 million +29.7%12.4%9.8 $21.50
2/28/20223,640,000 shares $81.65 million +8.7%9.5%7.6 $22.43
2/15/20223,350,000 shares $80.03 million +23.2%8.8%7.7 $23.89
1/31/20222,720,000 shares $66.45 million -13.1%7.1%6.7 $24.43
1/15/20223,130,000 shares $86.20 million -1.6%8.1%9.5 $27.54
12/31/20213,180,000 shares $102.40 million +6.0%8.3%10.9 $32.20
12/15/20213,000,000 shares $91.50 million +8.3%7.8%11 $30.50
11/30/20212,770,000 shares $102.82 million +0.4%7.2%10.6 $37.12
11/15/20212,760,000 shares $115.09 million +2.2%7.2%10.3 $41.70
10/29/20212,700,000 shares $119.93 million +1.5%7.0%9.9 $44.42
10/15/20212,660,000 shares $116.75 million No Change6.9%8.7 $43.89
9/30/20212,660,000 shares $118.85 million +17.2%6.9%7.9 $44.68
9/15/20212,270,000 shares $110.75 million -6.2%5.9%5.7 $48.79
8/31/20212,420,000 shares $97.11 million -11.7%6.6%5.5 $40.13
8/13/20212,740,000 shares $107.82 million +3.4%7.4%6 $39.35
7/30/20212,650,000 shares $114.32 million No Change8.1%5.5 $43.14
7/15/20212,650,000 shares $98.90 million -5.0%8.1%5.8 $37.32
6/30/20212,790,000 shares $105.57 million +18.2%8.5%6 $37.84
6/15/20212,360,000 shares $88.88 million -3.7%7.2%5.5 $37.66

CCCC Short Interest - Frequently Asked Questions

Short interest is the volume of C4 Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 29th, traders have sold 21,650,001 shares of CCCC short. 20.74% of C4 Therapeutics' shares are currently sold short. Learn More on C4 Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CCCC shares currently have a short interest ratio of 9.4. Learn More on C4 Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 20.74% of C4 Therapeutics' floating shares are currently sold short.

C4 Therapeutics saw a increase in short interest during the month of May. As of May 29th, there was short interest totaling 21,650,001 shares, an increase of 1.9% from the previous total of 21,254,462 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

20.74% of C4 Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to C4 Therapeutics: Agios Pharmaceuticals, Inc. (12.31%), Taysha Gene Therapies, Inc. (13.03%), Ascentage Pharma Group International - Unsponsored ADR (0.00%), Compass Pathways PLC Sponsored ADR (5.59%), Tyra Biosciences, Inc. (17.84%), Nurix Therapeutics, Inc. (20.03%), Sionna Therapeutics, Inc. (10.83%), SELLAS Life Sciences Group, Inc. (31.43%), Syndax Pharmaceuticals, Inc. (19.58%), Palvella Therapeutics, Inc. (18.58%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($81.27 billion), Invesco QQQ ($49.06 billion), iShares Russell 2000 ETF ($23.61 billion), Western Digital Corporation ($16.93 billion), Sandisk Corporation ($15.61 billion), Salesforce Inc. ($11.65 billion), SPDR S&P Biotech ETF ($10.52 billion), Nebius Group N.V. ($10.24 billion), Lumentum Holdings Inc. ($8.74 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($8.21 billion). View all of the most shorted stocks.

Short selling CCCC is an investing strategy that aims to generate trading profit from C4 Therapeutics as its price is falling. CCCC shares are trading up $0.29 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for C4 Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CCCC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CCCC, twice per month. The most recent reporting period available is May, 29 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like CCCC:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:CCCC) was last updated on 6/10/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Important SpaceX PREDICTION
The biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian s...
Banyan Hill Publishing | Sponsoredtc pixel